Bending To Overwhelming Feedback, CMS Softens Stance On PET For Solid Tumors
This article was originally published in The Gray Sheet
In a final decision memo released June 11, the Medicare agency provides national coverage for three post-cancer-treatment PET scans. The original coverage proposal would have allowed only one.
You may also be interested in...
While National Oncologic PET Registry data has been effective in persuading CMS to remove evidence-development restrictions from positron emission tomography coverage policies in the past, NOPR data was not enough to support coverage of PET scans to identify bone metastasis in a Dec. 15 national coverage determination.
Alzheimer’s researchers are planning to join with industry in a unified response to a Medicare coverage proposal that would, in their view, disastrously constrain use of positron emission tomography, and imaging agents like Eli Lilly’s Amyvid, in the diagnosis and management of Alzheimer’s patients.
Alzheimer’s community stakeholders are planning a unified response to a CMS Medicare coverage proposal that would, in their view, disastrously constrain use of PET imaging, and imaging agents like Lilly’s Amyvid, in the diagnosis and management of Alzheimer’s patients.